Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29122810 | 0.97 | EPHX1 (0.39) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL14473686 | 0.97 | EPHX1 (0.39) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL8211786 | 0.89 | TSHR (0.40) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL11814849 | 0.79 | KEAP1 (0.41) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL6255794 | 0.79 | KEAP1 (0.41) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL29051500 | 0.77 | EPHX1 (0.38) | KEAP1NFE2L2EPHX1ALDH1A1SSTR4 | |
| SCHEMBL28730098 | 0.77 | KEAP1 (0.44) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL1733953 | 0.77 | EPHX1 (0.39) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL1876976 | 0.77 | EPHX1 (0.39) | KEAP1NFE2L2EPHX1ALDH1A1TSHR | |
| SCHEMBL21269303 | 0.75 | EPHX1 (0.38) | KEAP1NFE2L2EPHX1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-3970684-A | Polyunsaturated prostaglandin derivatives | SYNTEX (U.S.A.) INC. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3931297-A | 10-Hydroxy PGC compounds | SYNTEX (U.S.A.) INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | KEAP1 1032/4885NFE2L2 2926/4885EPHX1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.